190 related articles for article (PubMed ID: 33109397)
1. Design, synthesis and bioevaluation of inhibitors targeting HSP90-CDC37 protein-protein interaction based on a hydrophobic core.
Zhang Q; Wu X; Zhou J; Zhang L; Xu X; Zhang L; You Q; Wang L
Eur J Med Chem; 2021 Jan; 210():112959. PubMed ID: 33109397
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer.
Wang L; Zhang L; Li L; Jiang J; Zheng Z; Shang J; Wang C; Chen W; Bao Q; Xu X; Jiang Z; Zhang J; You Q
Sci Adv; 2019 Sep; 5(9):eaax2277. PubMed ID: 31555737
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer.
Wang L; Jiang J; Zhang L; Zhang Q; Zhou J; Li L; Xu X; You Q
J Med Chem; 2020 Feb; 63(3):1281-1297. PubMed ID: 31935086
[TBL] [Abstract][Full Text] [Related]
4. Rational design of peptide inhibitors targeting HSP90-CDC37 protein-protein interaction.
Zhang Q; Yan L; Zhang Y; Zhang L; Yu J; You Q; Wang L
Future Med Chem; 2024 Jan; 16(2):125-138. PubMed ID: 38189168
[No Abstract] [Full Text] [Related]
5. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
[TBL] [Abstract][Full Text] [Related]
6. Structure-based virtual screening and optimization of modulators targeting Hsp90-Cdc37 interaction.
Wang L; Li L; Zhou ZH; Jiang ZY; You QD; Xu XL
Eur J Med Chem; 2017 Aug; 136():63-73. PubMed ID: 28482218
[TBL] [Abstract][Full Text] [Related]
7. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Novel Celastrol Derivatives as Hsp90-Cdc37 Interaction Disruptors with Antitumor Activity.
Li N; Xu M; Wang B; Shi Z; Zhao Z; Tang Y; Wang X; Sun J; Chen L
J Med Chem; 2019 Dec; 62(23):10798-10815. PubMed ID: 31725288
[TBL] [Abstract][Full Text] [Related]
9. Expression and purification of recombinant NRL-Hsp90α and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening.
He J; Niu X; Hu C; Zhang H; Guo Y; Ge Y; Wang G; Jiang Y
Protein Expr Purif; 2013 Nov; 92(1):119-27. PubMed ID: 24056254
[TBL] [Abstract][Full Text] [Related]
10. Medium-Throughput Detection of Hsp90/Cdc37 Protein-Protein Interaction Inhibitors Using a Split
Siddiqui FA; Parkkola H; Manoharan GB; Abankwa D
SLAS Discov; 2020 Feb; 25(2):195-206. PubMed ID: 31662027
[TBL] [Abstract][Full Text] [Related]
11. Targeting the HSP90-CDC37-kinase chaperone cycle: A promising therapeutic strategy for cancer.
Wang L; Zhang Q; You Q
Med Res Rev; 2022 Jan; 42(1):156-182. PubMed ID: 33846988
[TBL] [Abstract][Full Text] [Related]
12. Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins.
Smith JR; de Billy E; Hobbs S; Powers M; Prodromou C; Pearl L; Clarke PA; Workman P
Oncogene; 2015 Jan; 34(1):15-26. PubMed ID: 24292678
[TBL] [Abstract][Full Text] [Related]
13. Optimization and bioevaluation of Cdc37-derived peptides: An insight into Hsp90-Cdc37 protein-protein interaction modulators.
Wang L; Li L; Fu WT; Jiang ZY; You QD; Xu XL
Bioorg Med Chem; 2017 Jan; 25(1):233-240. PubMed ID: 27818030
[TBL] [Abstract][Full Text] [Related]
14. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
[TBL] [Abstract][Full Text] [Related]
15. Design of Disruptors of the Hsp90-Cdc37 Interface.
D'Annessa I; Hurwitz N; Pirota V; Beretta GL; Tinelli S; Woodford M; Freccero M; Mollapour M; Zaffaroni N; Wolfson H; Colombo G
Molecules; 2020 Jan; 25(2):. PubMed ID: 31952296
[TBL] [Abstract][Full Text] [Related]
16. Targeting CDC37: an alternative, kinase-directed strategy for disruption of oncogenic chaperoning.
Smith JR; Workman P
Cell Cycle; 2009 Feb; 8(3):362-72. PubMed ID: 19177013
[TBL] [Abstract][Full Text] [Related]
17. Coordinated regulation of serum- and glucocorticoid-inducible kinase 3 by a C-terminal hydrophobic motif and Hsp90-Cdc37 chaperone complex.
Wang Y; Xu W; Zhou D; Neckers L; Chen S
J Biol Chem; 2014 Feb; 289(8):4815-26. PubMed ID: 24379398
[TBL] [Abstract][Full Text] [Related]
18. Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites.
Eckl JM; Scherr MJ; Freiburger L; Daake MA; Sattler M; Richter K
J Biol Chem; 2015 Dec; 290(52):30843-54. PubMed ID: 26511315
[TBL] [Abstract][Full Text] [Related]
19. Exploring Biomolecular Interaction Between the Molecular Chaperone Hsp90 and Its Client Protein Kinase Cdc37 using Field-Effect Biosensing Technology.
Lerner Y; Sukumaran S; Chua MS; So SK; Qvit N
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35435890
[TBL] [Abstract][Full Text] [Related]
20. Cdc37 (cell division cycle 37) restricts Hsp90 (heat shock protein 90) motility by interaction with N-terminal and middle domain binding sites.
Eckl JM; Rutz DA; Haslbeck V; Zierer BK; Reinstein J; Richter K
J Biol Chem; 2013 May; 288(22):16032-42. PubMed ID: 23569206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]